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background:  There is little recent information on the long-term prognosis and treatment of patients with prior myocardial infarction (MI). 
The role of dual antiplatelet therapy (DAPT) in these patients is under investigation in the PEGASUS-TIMI 54 trial. This study evaluated 
current management and prognosis of prior MI patients free of cardiovascular (CV) events at 1 year in EPICOR (a prospective registry of 
ACS survivors recruited from 555 hospitals in 20 countries between 09/2010 and 03/2011).
methods:  The treatment and outcomes of 4,287 MI patients aged >50 years, ≥1 risk factor (age ≥65 years, diabetes mellitus, another prior 
MI, established multivessel coronary disease or chronic renal impairment) and free of CV events at 1 year were evaluated. This cohort 
comprised 40.6% of the 10,568 patients enrolled in EPICOR.
Results:  Baseline characteristics were: mean age 66 years, male 74%, STEMI 54%. Use of evidence-based therapies at discharge 
was high: 92.5% DAPT, 86.8% β-blockers, 79.5% renin-angiotensin system antagonists, 93.7% statins. At 1 year, 83.3% (3,256 of 3,907 
available for long-term analysis) were on DAPT. Between 1 and 2 years, 117 of 4,287 patients (2.7%) died (Figure), 49 (1.1%) had a new 
MI, and 6 (0.1%) had an ischemic stroke. At 2 years, the incidence of death/MI/stroke was 3.8% and the incidence of major bleeding 
leading to hospitalization was 1.1%.
conclusion:  Despite high compliance with recommended medical therapies at 1 year, the mortality rate in patients with prior MI remains a 
concern.
